The obesity drug market heats up as Novo Nordisk launches a rival $8.5 billion bid for Metsera, directly challenging Pfizer’s existing offer. This bidding war signals intensifying competition for dominance in the lucrative weight-loss treatment space with significant implications for both companies’
Artificial intelligence company Anthropic is adapting its Claude chatbot specifically for life sciences research and pharmaceutical development. Early adopters including Novo Nordisk and Sanofi have reported dramatic reductions in documentation time and widespread employee adoption of the AI tools.
Artificial intelligence startup Anthropic is customizing its Claude chatbot specifically for researchers and life sciences companies, according to reports, as technology groups race to develop specialized applications from artificial intelligence technology. The San Francisco-based company reportedly announced on Monday that it is integrating Claude into scientific tools that researchers already use, including laboratory management systems, genomic analysis platforms, and biomedical databases.
